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Abstract
Background: Population mean changes are difficult to use in clinical practice. Responder analysis may be better, but 
needs validating for level of response and treatment duration. A consensus group has defined what constitutes 
minimal, moderate, and substantial benefit based on pain intensity and Patient Global Impression of Change scores.
Methods: We obtained individual patient data from four randomised double blind trials of pregabalin in fibromyalgia 
lasting eight to 14 weeks. We calculated response for all efficacy outcomes using any improvement (≥ 0%), minimal 
improvement (≥ 15%), moderate improvement (≥ 30%), substantial improvement (≥ 50%), and extensive improvement 
(≥ 70%), with numbers needed to treat (NNT) for pregabalin 300 mg, 450 mg, and 600 mg daily compared with 
placebo.
Results: Information from 2,757 patients was available. Pain intensity and sleep interference showed reductions with 
increasing level of response, a significant difference between pregabalin and placebo, and a trend towards lower 
(better) NNTs at higher doses. Maximum response rates occurred at 4-6 weeks for higher levels of response, and were 
constant thereafter. NNTs (with 95% confidence intervals) for ≥ 50% improvement in pain intensity compared with 
placebo after 12 weeks were 22 (11 to 870) for pregabalin 300 mg, 16 (9.3 to 59) for pregabalin 450 mg, and 13 (8.1 to 
31) for pregabalin 600 mg daily. NNTs for ≥ 50% improvement in sleep interference compared with placebo after 12 
weeks were 13 (8.2 to 30) for pregabalin 300 mg, 8.4 (6.0 to 14) for pregabalin 450 mg, and 8.4 (6.1 to 14) for pregabalin 
600 mg. Other outcomes had fewer respondents at higher response levels, but generally did not discriminate between 
pregabalin and placebo, or show any dose response. Shorter duration and use of 'any improvement' over-estimated 
treatment effect compared with longer duration and higher levels of response.
Conclusions: Responder analysis is useful in fibromyalgia, particularly for pain and sleep outcomes. Some fibromyalgia 
patients treated with pregabalin experience a moderate or substantial pain response that is consistent over time. Short 
trials using 'any improvement' as an outcome overestimate treatment effects.
Background
Fibromyalgia is surrounded by controversy regarding its
aetiology and its status as a valid disease entity. Genetic
and neurobiological evidence now exists to support dif-
ferences between fibromyalgia patients and controls [1].
Candidate biomarkers identifying susceptible individuals
or indicating disease activity are emerging, [2] along with
a better understanding of outcomes in clinical trials [3].
Fibromyalgia is characterised by widespread pain for
longer than three months with pain on palpation at 11 or
more of 18 specified tender points [4]. Sleep disturbance,
depression, and fatigue often complicate the clinical pic-
ture [5]. Fibromyalgia is common, occurring in 1-2% of
the population, more often in women than men, [6-8] and
often with profound impact on activities of daily living
and productivity [9,10].
It is increasingly recognised that medicines typically
provide a good response in half or fewer of patients
treated [11,12]. This is true in acute pain, [13] neuro-
pathic pain, [14-16] migraine, [17] and osteoarthritis
[18,19].
Here we present an analysis of the efficacy of pregabalin
in fibromyalgia using individual patient data from four
randomised, double blind, placebo controlled trials
(RCTs). With this analysis we aimed to identify which
outcomes were appropriate for a responder analysis
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Pain Assessment in Clinical Trials (IMMPACT) consen-
sus statement on interpreting changes in chronic pain
clinical trial outcomes [20]. This suggested that for pain, a
minimally important improvement was a 10-20%
decrease in pain intensity, a moderately important
improvement a decrease of 30% or more, and a substan-
tial improvement a decrease of 50% or more. It also sug-
gested that responses in Patient Global Impression of
Change of minimally improved, much improved, and
very much improved would also constitute minimally
important, moderately important, and substantial
improvements.
IMMPACT defined response in dimensions other than
pain, including physical and emotional functioning, as
well as global rating of improvements. In theory, any
measurement on any scale could be used for a responder
analysis, with a wide range of possibilities of what consti-
tutes a responder. The use of change from baseline, with
several different levels of response, should allow an
assessment of the utility of both the scale, and the level of
response. Utility can be assessed by the occurrence of sta-
tistically or clinically significant differences between
active therapy and placebo for a particular scale, espe-
cially if there appears to be a dose response. The absence
of a significant difference between an effective therapy
and placebo at all levels of response would be an indica-
tion that that particular scale lacks utility for measuring
response in a particular circumstance.
The particular circumstance of fibromyalgia is interest-
ing because many different measurements are made
using different scales, allowing different scales and levels
of response to be examined.
Methods
Pfizer Inc provided Excel files containing individual
patient data from four multi-centre clinical phase 2/3 or
phase 3 RCTs of pregabalin (Lyrica) in the treatment of
fibromyalgia that were conducted in the USA and other
countries and were completed by July 2008 (trials 105,
[21] 1056, [22] 1077, [23] 1100 [24]). Pfizer Inc also pro-
vided PDF files of the corresponding company clinical
trial reports. A trial of enriched enrolment randomised
withdrawal design ("FREEDOM trial", 1059 [25]) was not
included in our analysis because it was fundamentally dif-
ferent [26].
Trial patients were at least 18 years old. Women were
not pregnant or lactating, and either postmenopausal,
surgically sterilised, or using contraception. Important
exclusion criteria were: severe pain due to other condi-
tions, rheumatic diseases other than fibromyalgia, active
infections, untreated endocrine disorders, severe depres-
sion, active malignancy, being immunocompromised,
other severe acute or chronic medical or psychiatric con-
ditions, or laboratory abnormalities. Trial patients had to
fulfil ACR criteria for fibromyalgia and have pain scores
of ≥ 40 mm on the 100 mm visual analogue scale (VAS)
after stopping any relevant pain or sleep medication.
Patients were randomised to receive pregabalin (150 mg,
300 mg, 450 mg, or 600 mg per day), or placebo, predom-
inantly with a 2-week dose escalation phase followed by
fixed dosing for up to 14 weeks of total trial duration.
We calculated the proportion of patients achieving
reductions in pain scores of any improvement (≥ 0%), ≥
15%, ≥ 30%, ≥ 50%, and ≥ 70% compared to baseline pain
scores between weeks 1-12. Sleep improvement was cal-
culated in an analogous manner from weekly averages of
sleep quality scores. Improvements in end of trial out-
comes (Hospital Anxiety and Depression Scale [HADS],
Fibromyalgia Impact Questionnaire [FIQ], Short Form 36
[SF-36] domains, Multidimensional Assessment of
Fatigue [MAF] global index, Patient Global Impression of
Change [PGIC], Medical Outcomes Study [MOS] Sleep
Disturbance, and MOS 9-item Sleep Problem Index),
were calculated by comparing data at the trial endpoints
with baseline data and calculating the percentage
improvement with the individual baseline score set as
100%. We chose levels of improvement for non-pain out-
comes also at the above-mentioned cut-points in order to
allow ready comparison with pain as an outcome,
although it has to be kept in mind that those cut-points
do not necessarily have the same clinical relevance for
non-pain outcomes as they do for pain (where they have
been validated).
The following two rules were applied to the data set to
handle missing data.
• For patients who did not drop out, only actual mea-
sured values were used for calculations. Last observa-
tion carried forward was not used except where no 
other data were available (for end of trial outcomes in 
trial 105 and for HADS outcomes from all trials).
• From discontinuation day forward patients were 
assigned 0% improvement.
A responder is then defined as any patient who
achieves at least the predefined level of change specified
or greater. For example, a patient with exactly 50% pain
relief and a patient with 57% pain relief would both be
counted as responders at the 50% level.
Trial quality was assessed using the Oxford Quality
Scale [27]. Validity was scored using the Oxford Pain
Validity Scale [28]. The minimum requirement for inclu-
sion in this responder analysis was that trials had to be
both randomised and double blind.
Calculations of responder rates and numbers needed to
treat (NNT) were performed independently of Pfizer
using a spreadsheet consultancy (Spreadsheet Factory --
http://www.spreadsheet-factory.com) run by one of the
authors (Jocelyn Paine). Response data were pooled and
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domised patients who received at least one dose of trial
drug. We calculated the number and percentage of
responders for each level of response (≥ 0%, ≥ 15%, ≥ 30%,
≥ 50%, and ≥ 70% improvement compared to baseline
pain scores), pregabalin dose (300 mg, 450 mg, or 600 mg
per day), and time point (per week of trial or at end of
trial, as detailed in the figures and tables). NNTs were cal-
culated with 95% confidence intervals by the method of
Cook and Sackett, [29] using the pooled number of
observations. NNTs were not calculated when statistical
significance was not achieved; in this circumstance NNTs
can approach infinity (100/absolute risk difference), with
one of the confidence limits being negative. Only data
from trials that included a particular pregabalin dose
were used for calculations for that dose; only the placebo
data from the specific trials which included that specific
dose were used in each dosing comparison. The intention
was to analyse data only where there were at least 200
patients in at least two trials [30].
For responder analysis to be useful we hypothesised
that its should produce stepped reductions in the per-
centage of patients responding with increasing level of
response, a significant difference between pregabalin and
placebo in the number of responders at a particular level,
and a trend towards lower (better) NNTs at higher doses
of pregabalin, given that pregabalin has been shown in
randomised trials and meta-analysis to be effective in
fibromyalgia, with higher doses being more effective and
with more adverse events [31]. Any scale without these
features would be unlikely to have any utility for a
responder analysis in fibromyalgia.
Results
Patient and trial characteristics
In the four trials 2757 patients aged between 18 and 82
years were treated with pregabalin or placebo. More than
90% were women. One trial lasted 8 weeks (trial 105); the
others lasted 13 or 14 weeks. All trials were of high qual-
ity and validity, scoring 5/5 on the Oxford Quality Scale
and 16/16 on the Oxford Pain Validity Scale. Pregabalin
doses of 300 mg (685 patients) and 450 mg (687 patients)
were used in all four trials, 600 mg (564 patients) was
used in three, and 150 mg (132 patients) in one; placebo
was given to 689 patients. We used doses of 300 mg, 450
mg, and 600 mg in our pooled analysis.
Weekly pain response rates
Data for weekly pain response with pregabalin 450 mg
daily are shown in Figure 1. Additional file 1 compares
the weekly pain response with pregabalin 300-600 mg
daily and placebo. Numerical data for six and 12 weeks
are presented in Table 1. Over time the number of
patients reporting 'any improvement' fell and the number
reporting the higher response levels of at least 50% or at
least 70% improvement increased, demonstrating that
change in recorded pain intensity was a sensitive indica-
tor for a responder analysis. This was apparent for pla-
cebo and all pregabalin doses, especially over the first six
weeks. At 6 weeks the proportion with at least 50% pain
relief, a substantial improvement, reached a steady state.
After 12 weeks 38% of those treated with 450 mg pregab-
alin had a moderate response or better, 21% a substantial
response, and 8.5% an extensive response.
The corresponding NNTs (Table 1, Additional file 2)
generally increased over time for all response levels. At 12
weeks, 11 people need to be treated with pregabalin 450
mg daily rather than with placebo for one of them to
achieve a moderate benefit of at least 30% pain relief.
Weekly sleep response rates
Figure 2 and Additional files 3 and 4 illustrate the per-
centages of patients achieving the indicated response lev-
els for sleep improvement over time and the
corresponding NNTs. The results for sleep response were
similar to pain relief, demonstrating that change in sleep
was a sensitive indicator for a responder analysis. After 12
weeks with 450 mg pregabalin daily 40% had ≥ 30%
improvement, 26% had ≥ 50% improvement, and 10% had
≥ 70% improvement (Table 1).
The corresponding NNTs (Table 1, Additional file 4)
generally increased over time for all response levels. At 12
weeks, 7 people need to be treated with pregabalin 450
mg daily rather than with placebo for one of them to
achieve a moderate benefit of at least 30% reduction in
sleep interference.
Patient Global Impression of Change
Figure 3 shows the proportion of patients achieving a
PGIC rating of very much improved, at least much
improved, or at least some improvement at end of study.
For the higher hurdles of improvement (much and very
much improved), pregabalin was more effective than pla-
cebo and a dose response was apparent, although 600 mg
daily produced slightly lower levels of improvement than
450 mg. Using 'any improvement' as a measure of effi-
cacy, no consistent and convincing benefit of pregabalin
over placebo was apparent. This demonstrates that
Patient Global Impression of Change was a sensitive indi-
cator for a responder analysis. NNTs and actual values
are shown in Table 2; best sensitivity was shown with 450
mg and the cumulative outcome of much and very much
improved.
Other outcomes
Additional file 5 shows responder analyses for a number
of other outcomes, including the MAF global fatigue
index, FIQ, and HADS depression and anxiety scores, as
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measure SF-36.
Most of these demonstrated sensitivity, in that the pro-
portion of responders fell with increasing levels of
response, though this was less marked with some of the
individual domains of SF-36, particularly physical and
emotional role limitations, social functioning, bodily
pain, and vitality. For these the differential between low-
est and highest levels of response was not large. Sensitiv-
ity to detect an effect of pregabalin treatment defined by
statistical significance over placebo to enable NNT to be
calculated was apparent for MOS Sleep Disturbance,
MOS Sleep Problems Index, and SF-36 general health
perception, bodily pain, and vitality.
Discussion
Analyses presented here involved 2,757 patients with
ACR-defined fibromyalgia investigated in high quality
randomised double blind trials for eight to 14 weeks. This
represents the largest body of evidence available in fibro-
myalgia, more than double the number of patients inves-
tigated in three trials of duloxetine, [16] and four times
that with amitriptyline [32]. Moreover, analyses involved
a large number of different measures at five different lev-
els of efficacy.
The principal findings were that simple outcomes like
pain, sleep, and PGIC were amenable to responder analy-
sis. They demonstrated stepped reductions in value with
increasing level of response, showed a significant differ-
ence between pregabalin and placebo, and a trend
towards lower (better) NNTs at higher doses of pregaba-
lin. With our approach (responder analysis based on per-
centage change from baseline) this was not generally the
case with less simple outcomes, including fatigue, Fibro-
myalgia Impact Questionnaire scores, anxiety, depres-
sion, and most domains of SF-36, apart perhaps vitality.
Table 1: Pain and sleep responses at different response levels and doses of pregabalin
Percent with treatment/placebo NNT (95% CI)
Outcome Level Placebo 300 mg 450 mg 600 mg 300 mg 450 mg 600 mg
Pain: change from baseline ≥ 0% 60 65 68 60 not calculated 13 (8.0 to 41) not calculated
6 weeks ≥ 15% 44 52 56 52 13 (7.8 to 43) 8.4 (5.8 to 15) 14 (7.6 to 67)
≥ 30% 28 36 39 39 10 (6.9 to 21) 8.0 (5.7 to 13) 8.5 (5.8 to 16)
≥ 50% 14 21 23 26 14 (8.8 to 30) 12 (7.9 to 22) 8.8 (6.2 to 15)
≥ 70% 4.1 7.7 9.0 12 30 (17 to 110) 19 (13 to 38) 14 (9.8 to 26)
Pain: change from baseline ≥ 0% 54 55 60 53 not calculated not calculated not calculated
12 weeks ≥ 15% 40 45 49 43 not calculated 12 (6.9 to 35) not calculated
≥ 30% 29 33 38 34 not calculated 11 (6.9 to 29) not calculated
≥ 50% 15 19 21 23 22 (11 to 870) 16 (9.3 to 59) 13 (8.1 to 31)
≥ 70% 5.9 6.8 8.5 12 not calculated not calculated 18 (11 to 43)
Sleep: change from baseline ≥ 0% 59 64 68 61 not calculated 11 (7.0 to 23) not calculated
6 weeks ≥ 15% 45 53 55 51 11 (7.2 to 29) 9.3 (6.3 to 18) 15 (8.0 to 130)
≥ 30% 29 39 43 41 9.4 (6.4 to 17) 6.8 (5.1 to 10) 8.2 (5.7 to 15)
≥ 50% 13 25 26 26 9.0 (6.6 to 14) 7.8 (5.9 to 12) 7.7 (5.7 to 12)
≥ 70% 3.8 11 13 13 14 (10 to 23) 11 (8.6 to 17) 12 (8.8 to 21)
Sleep: change from baseline ≥ 0% 51 54 58 52 not calculated 14 (7.6 to 68) not calculated
12 weeks ≥ 15% 37 43 49 44 not calculated 8.9 (5.9 to 19) 16 (8.3 to 170)
≥ 30% 25 32 40 35 14 (8.1 to 58) 7.0 (5.1 to 11) 10 (6.6 to 22)
≥ 50% 14 21 26 26 13 (8.2 to 30) 8.4 (6.0 to 14) 8.4 (6.1 to 14)
≥ 70% 5.0 9.3 10 12 24 (14 to 82) 20 (13 to 55) 14 (9.4 to 24)
NNTs were not calculated when statistical significance was not achieved.
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ably not suitable for most of the outcome measures iden-
tified in fibromyalgia clinical trials [3].
A minority of patients experience substantial or moder-
ate benefit, though always significantly more than with
placebo, whichever IMMPACT definition of benefit is
used. Similar levels of response have been seen for dulox-
etine, amitriptyline, and tramadol/paracetamol in fibro-
myalgia, [16,32,33] and in osteoarthritis [19].
Weekly analyses for changes in pain intensity and sleep
interference demonstrated that maximum benefits for
moderate (≥ 30%), substantial (≥ 50%), or extensive (≥
70%) response occurred at four to six weeks, and thereaf-
ter remained reasonably constant. By contrast, response
rates for any benefit (≥ 0%) and minimal benefit (≥ 15%)
dropped over 12 weeks. Those with a useful response for
pain and sleep tend to continue with the treatment; those
not achieving moderate or substantial improvement after
4-6 weeks are unlikely to do so later and may be better
served by alternative therapies. Pregabalin seemed
equally effective at treating pain and sleep disturbance in
fibromyalgia, though it is not clear if these improvements
occurred in the same patients.
NNTs for reduction in pain intensity and sleep interfer-
ence calculated at different levels of response at weekly
intervals increased with time for all three doses of
pregabalin. An increase in NNTs over time has been seen
before in arthritis [19]. It may represent either increasing
discontinuation rates over time, perhaps because of
adverse events with active therapy, or patients who had
previously achieved a response at a given level now expe-
riencing a decrease in their magnitude of improvement to
below the level in question, or some combination of
these. Discontinuations can be different between thera-
pies, with more adverse event discontinuations with
active therapy, and more lack of efficacy discontinuations
with placebo, and these may have different timescales
[34].
Changing NNTs over time are an important finding
with implications for efficacy comparisons between
drugs. Drugs tested in shorter duration trials (six weeks
or less) are likely to appear more effective than the same
drug in longer duration trials (eight weeks or more). Four
of 10 randomised trials of amitriptyline in fibromyalgia
were of six weeks or less, [32] though those of duloxetine
were of 12 weeks duration, [16] as was that of a tramadol/
paracetamol combination [33].
For the PGIC rating at the end of the trial, higher levels
of improvement showed pregabalin to be progressively
less effective, at least when NNTs were considered. This
illustrates the problem with using 'any improvement' as
an outcome, as has been the case in many neuropathic
Figure 1 Weekly pain response levels compared to baseline. For 





































Figure 2 Weekly sleep response levels compared to baseline. For 
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Page 6 of 8pain studies in the past. Use of 'any improvement' as an
outcome overestimated efficacy compared with more
substantial levels of improvement.
Table 2 shows that PGIC response rates for 'improve-
ment' decreased at 600 mg pregabalin compared with the
450 mg dose. Perhaps 450 mg is the optimal treatment
dose for fibromyalgia (as PGIC takes therapeutic efficacy
and adverse events into account). However, it has to be
kept in mind that the dose of 450 mg pregabalin was used
in all four trials (687 patients) while 600 mg pregabalin
was used in only three of them (564 patients). Some inter-
trial variability may therefore potentially also play a role.
The strengths of our analysis are that we analysed a
large number of individual patient data in a clinically
important chronic pain condition, using validated instru-
ments for measuring clinically important trial outcomes,
based on large, modern, rigorous, and methodologically
sound trials. Our approach is limited in that we have
analysed individual patient data for the drug treatment of
fibromyalgia for only one agent (pregabalin). More indi-
vidual patient analyses with other treatments for fibromy-
algia are needed to confirm that our findings are
generalisable. Finally, any work on fibromyalgia as it is
presently defined is limited because 'fibromyalgia' is
probably a heterogeneous group of clinical entities with
multifaceted patterns of pain, driven by complex path-
ways of neural mechanisms in which different pathways
and mechanisms are not clearly correlated with different
pain patterns, likely to be different between individuals,
and further complicated by co-morbid conditions and
increased age. Chronic pain is associated with functional,
structural, and chemical changes in the brain, including
loss of gray matter [35]. Individual variability in physio-
logical response to analgesic drugs may be genetic, as for
NSAIDs, [36] opioids, [37] and more generally, [38] and
indeed varies in extent between different conditions, as
with pregabalin in peripheral neuropathic pain, central
neuropathic pain, and fibromyalgia [39]. Ongoing
genetic, neurobiological, and biomarker work in fibromy-
algia [1,2] may one day help to classify patients more
appropriately and allow targeted treatment.
Conclusions
Quite large differences in response levels between indi-
viduals with fibromyalgia are to be expected, and were
found in this analysis, where responder rates with pregab-
alin were higher than with placebo. Responder analysis in
fibromyalgia looks promising. However, responder analy-
sis in the form that we have undertaken in this paper
(using percentage change from baseline) is appropriate
only for certain outcomes (such as pain and sleep) and
not for others; it is informative where it works but not
universally applicable. The full potential and limitations
of responder analysis will be realised only when more
data can be analysed and compared.
List of abbreviations
ACR: American College of Rheumatology; CI: confidence
interval; NNT: number needed to treat; NSAID: non-ste-
roidal anti-inflammatory drug; RCT: randomised con-
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Table 2: PGIC responses at end of study
Percent with treatment/placebo NNT (95% CI)
Improvement Placebo 300 mg 450 mg 600 mg 300 mg 450 mg 600 mg
At least minimal 45 54 59 47 11 (7.1 to 28) 7.3 (5.3 to 12) not calculated
At least much 25 32 36 33 14 (8.5 to 44) 8.9 (6.2 to 16) 13 (7.7 to 41)
Very much 6.7 11 11 10 26 (15 to >100) 24 (14 to 80) not calculated
Figure 3 Patient Global Impression of Change. The proportion of 
patients achieving a rating of at least some improvement, at least 
much improved, or very much improved.
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